Macular Edema Nepafenac vs. Difluprednate Uveitis Trial (MEND)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01939691 |
Recruitment Status :
Terminated
(Difficulty enrolling)
First Posted : September 11, 2013
Last Update Posted : January 13, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Macular edema is a condition in which there is swelling in the macula, the part of the retina that gives you your best vision. This swelling can cause your vision to decline. When diagnosed early and treated, you vision usually can be preserved. However, if the swelling goes untreated for a long time, it can cause permanent vision loss.
We think that the three eye drop regimens in this study, difluprednate, difluprednate plus nepafenac, and prednisolone acetate plus nepafenac, might be effective in treating uveitic macular edema. Patients who enter this study are randomized to one of the three regimens and followed for 24 weeks.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Uveitis Macular Edema | Drug: Difluprednate Drug: Nepafenac Drug: Prednisolone acetate | Phase 4 |
Trial: Randomized 3 arm (1:1:1) parallel design comparative effectiveness trial
Stratification: Systemic corticosteroid/immunosuppressive therapy vs. none
Treatments: 1) difluprednate 0.05% 2) combination therapy of prednisolone acetate 1% with nepafenac 0.1% 3) combination therapy of difluprednate 0.05% with nepafenac 0.1%
Masking: Unmasked treatment administration; masked outcome assessment (evaluation of OCT and visual acuity)
Follow-up: 2, 4, 6, 8, and 24 weeks
Treatment protocol:
Patients will be randomized at enrollment to either:
- difluprednate 0.05% 4 drops per day
- prednisolone acetate 1% 4 drops per day and nepafenac 0.1% 3 drops per day
- difluprednate 0.05% 4 drops per day and nepafenac 0.1% 3 drops per day
If macular edema has not resolved at Week 4, continue study treatment at the same dose until Week 6.
If macular edema has resolved at Week 4, reduce study treatment as follows:
- difluprednate 0.05% 1 drop per day until Week 6, then stop
- prednisolone acetate 1% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 6, then stop
- difluprednate 0.05% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 6, then stop
If macular edema does not resolve at Week 4 but has resolved at Week 6, reduce study treatment at Week 6 as follows:
- difluprednate 0.05% 1 drop per day until Week 8, then stop
- prednisolone acetate 1% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 8, then stop
- difluprednate 0.05% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 8, then stop If macular edema resolves at Week 4 but reoccurs at Week 6, treat per best medical judgement.
After Week 8, there are no restrictions on the treatments patients may receive, and medications can be tapered further, discontinued, or changed at the discretion of the treating physician and patient preference. If a patient with previously resolved macular edema has a recurrence, the physician may treat according to best medical judgement.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 9 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Randomized 3 arm (1:1:1) parallel design comparative effectiveness trial |
Masking: | Single (Outcomes Assessor) |
Masking Description: | Masked outcome assessment (evaluation of OCT and visual acuity) |
Primary Purpose: | Treatment |
Official Title: | Macular Edema Nepafenac vs. Difluprednate Uveitis Trial |
Actual Study Start Date : | September 12, 2018 |
Actual Primary Completion Date : | March 31, 2020 |
Actual Study Completion Date : | March 31, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Difluprednate
Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
|
Drug: Difluprednate
Difluprednate 0.05% - corticosteroid eyedrop
Other Name: Durezol |
Experimental: Nepafenac plus Prednisolone acetate
Nepafenac 0.1% 3 times a day until resolution; prednisolone acetate 1% 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at Week 4, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until Week 6, then decrease to 1 drop per day until Week 8, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
|
Drug: Nepafenac
Nepafenac 0.1% - NSAID eyedrop
Other Name: Nevanac Drug: Prednisolone acetate prednisolone acetate 1% - corticosteroid eyedrop
Other Name: Pred Forte, Econo Pred |
Experimental: Difluprednate plus Nepafenac
Nepafenac 0.1% 3 times a day until resolution; Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
|
Drug: Difluprednate
Difluprednate 0.05% - corticosteroid eyedrop
Other Name: Durezol Drug: Nepafenac Nepafenac 0.1% - NSAID eyedrop
Other Name: Nevanac |
- Central subfield thickness [ Time Frame: 4 weeks ]Central subfield thickness measured by spectral domain optical coherence tomography adjusting for baseline thickness
- Resolution [ Time Frame: 4 weeks ]proportion of patients with resolution of macular edema
- Improvement [ Time Frame: 4 weeks ]proportion of patients with improvement in macular edema defined as 20% or greater reduction in central subfield thickness by OCT or resolution of edema
- recurrence [ Time Frame: 4 weeks ]proportion of patients with recurrence of macular edema defined as greater than 20% increase in central subfield thickness to a value >320 microns by OCT or presence of cysts in an eye that previously had resolution of macular edema
- Intraocular pressure (IOP) increase [ Time Frame: 4 weeks ]number of patients with intraocular pressure increase at least 10mmHg over baseline
- High IOP [ Time Frame: 4 weeks ]Number of patients experiencing high intraocular pressure (> 24 mmHg)
- Visual acuity [ Time Frame: 4 weeks ]best-corrected visual acuity (ETDRS protocol)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
108 patients with uveitic ME will be enrolled at Aravind Eye Hospital in Madurai, India based on the following eligibility criteria:
Patient-level Inclusion criteria:
- ≥18 years of age
- Diagnosis of anterior, intermediate, posterior, or panuveitis (can be infectious or non-infectious)
- Inactive or minimally active inflammation according to Standardization of Uveitis Nomenclature criteria (≤ 0.5+ Anterior Chamber (AC) cells, ≤ 0.5+ vitreous haze and no active retinal/choroidal lesions)
- If on oral corticosteroids, a stable dose of <10 mg prednisone/day for >4 weeks
- If on systemic corticosteroid-sparing immunomodulatory therapy, a stable dose for >4 weeks
- If using prednisolone acetate 1% drops, stable regimen of ≤2 drops per day for >4 weeks
- If infectious uveitis, inflammation must be inactive or minimally active per definition above and on stable dose of treatment for ≥4 weeks with no anticipated changes to treatment during the trial
Eye-level Inclusion Criteria
- ME defined as thickening of the 1mm central subfield of the macula greater than 2 standard deviations above normal thickness (>320 µm by Heidelberg spectral-domain OCT) with or without the presence of intraretinal cysts.
- Baseline intraocular pressure >5 mmHg and <21 mmHg (current use ≤3 intraocular pressure-lowering medications and/or prior glaucoma surgery are acceptable)
- Media clarity and pupillary dilation sufficient to allow OCT testing and retinal photography
- Best-corrected visual acuity of 5/200 or better
Patient-level Exclusion Criteria
- Use of oral acetazolamide or other systemic carbonic anhydrase inhibitors at baseline
- Known allergy or hypersensitivity to any component of the study drugs
- Women who are pregnant or breastfeeding (pregnancy test should be administered prior to baseline fluorescein angiogram)
- Patients unwilling or unable to not wear contact lenses during the study period
- History of central serous chorioretinopathy in either eye
Eye-level Exclusion Criteria
- Intravitreal or periocular corticosteroid injection in the past 8 weeks, dexamethasone implant in the past 12 months, or a fluocinolone acetonide implant in the past 3 years
- Presence of an epiretinal membrane-noted clinically or by OCT-in the study eye, thought to be significant enough to preclude improvement of ME
- Previous pars plana vitrectomy
- History of severe glaucoma (C/D ratio > 0.9 or any notching of optic nerve to rim)
- Prior use of difluprednate or nepafenac in the past 4 weeks

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01939691
India | |
Aravind Eye Hospital | |
Coimbatore, Tamil Nadu, India | |
Aravind Eye Hospital | |
Madurai, Tamil Nadu, India | |
Aravind Eye Hospital | |
Pondicherry, Tamil Nadu, India |
Principal Investigator: | Nisha Acharya, MD MS | University of California, San Francisco |
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT01939691 |
Other Study ID Numbers: |
18-24978 |
First Posted: | September 11, 2013 Key Record Dates |
Last Update Posted: | January 13, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
difluprednate prednisolone acetate nepafenac |
Macular Edema Uveitis Edema Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases Uveal Diseases Prednisolone Methylprednisolone Acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone acetate Nepafenac Prednisolone hemisuccinate |
Prednisolone phosphate Difluprednate Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents |